



**SDI Review Form 1.6**

Journal Name:	<a href="#">European Journal of Medicinal Plants</a>
Manuscript Number:	<b>Ms_EJMP_26453</b>
Title of the Manuscript:	<b>Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors</b>
Type of the Article	<b>Original Research Article</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<b>Not applicable.</b>	
<b>Minor</b> REVISION comments	<p>The majority of suggested revisions are regarding grammatical changes to provide clarity. Overall, the manuscript is technically sound. The materials and methods were well-constructed and appropriate for the analysis. The results and discussion section were well-controlled and references were appropriate. The conclusion was unbiased and supported by the results and discussion.</p> <p>I have two suggestions for enhancing the methods sections so that it is easily reproducible:</p> <p>Clarifications in Methods:</p> <ol style="list-style-type: none"> <li>Line 178: Include a definition for what is considered to be "high differences"</li> <li>Line 221: Include the names of the specific tests other than ANOVA that were used to make your comparisons</li> </ol> <p>Grammatical changes:</p> <ol style="list-style-type: none"> <li>Line 30 of abstract: Remove I in MAO-BIs - double negative and implies that you and inhibiting inhibitors</li> <li>Line 102 of manuscript: It seems you are missing a word here. I would suggest adding in diseases or disorders after "neurodegenerative"</li> </ol>	<p>Clarifications in Methods:</p> <ol style="list-style-type: none"> <li>Line 178: the definition for "high differences" was clarified as "Any extract with <math>\geq 50\%</math> scavenging or <math>\geq 30\%</math> quenching activities were excluded from the hMAO-A and hMAO-B inhibition extract screenings."</li> </ol> <p>As That information was in the results section, on line 253, to avoid repetition the line was modified to "Scavenging and quenching activities tests were performed on all 155 prepared extracts. That led to excluding 30 extracts from the hMAO-A and hMAO-B inhibition screen to eliminate their interferences."</p> <ol style="list-style-type: none"> <li>Line 221: The names of the specific tests other than ANOVA that were added to make the sentence as follows "One-way and two-way ANOVA were performed followed by multiple comparisons tests (Dunnett's after one-way ANOVA, and Sidak's after two-way ANOVA) to determine the significance of the difference between each two or more groups as</li> </ol>



**SDI Review Form 1.6**

	<ol style="list-style-type: none"> <li>3. Line 122: change "grounded" to "ground" - past tense of grind</li> <li>4. Line 127: change "drying" to "dry"</li> <li>5. Line 148: add period to close sentence</li> <li>6. Line 193: switch from "earlier mentioned" to "mentioned earlier"</li> <li>7. Line 252: change "exclusion" to "were excluded"</li> <li>8. Line 279: Rearrange phrase for clarity - change from "the ranked top RIB six extracts" to "the six top ranged RIB extracts"</li> <li>9. Line 368: change "hMAO-B inhibitions more than hMAO-A" to "inhibition of hMAO-B than hMAO-A"</li> <li>10. Line 388: change "is used" to "has been used"</li> </ol>	<p>expressed in the figures."</p> <p>The grammatical changes:</p> <ol style="list-style-type: none"> <li>1. Line 30 has been changed to the following "potent and selective inhibitions for MAO-B"</li> <li>2. Line 102 the word diseased was added: "neurodegenerative diseases such as PD."</li> <li>3. Line 122 (line 123 in modified manuscript): "grounded" was changed to "ground"</li> <li>4. Line 127: "to speed drying" changed to "for speed dry"</li> <li>5. Line 148: a period was added.</li> <li>6. Line 193: "earlier mentioned" switched to "mentioned earlier"</li> <li>7. Line 252: the sentence containing "exclusion" was modified to "That led to excluding 30 extracts from the screen."</li> <li>8. Line 279: "the ranked top RIB six extracts" were rearrange for clarity - change to "the six top ranged RIB extracts"</li> <li>9. Line 368 (370 in modified manuscript): change "hMAO-B inhibitions more than hMAO-A" to "inhibition of hMAO-B than hMAO-A"</li> <li>10. Line 388: "is used" was changed to "has been used"</li> </ol>
--	---	--



**SDI Review Form 1.6**

<b><u>Optional/General</u></b> comments	Line 63-64: consider revising to better reflect current clinical practice	<b>Line 63-64</b> was revised and rephrased as follows “ <b>Synthesized</b> monoamine oxidase-A and B inhibitors (MAO-AIs and MAO-BIs) <b>suspected side effects hindered them from being the first choice in therapy. However, they have been progressively proven effective</b> in Parkinson's disease (PD) and depression”.
---	---	---